Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
NEJM Studies Find New Carbamazepine Response Marker, Support Value of Genotyping in Han Chinese
March 23, 2011
The US Food and Drug Administration in 2007 updated the label for carbamazepine to recommend that patients of Asian ancestry taking the drug be tested for the HLA-B*1502 marker. While one NEJM study published this week supports this practice, a second study suggests that the boxed warning be expanded to include a new allele for the European population.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- Q&A: Matt Posard on Illumina's Clinically Focused Business Unit
March 14, 2012 / Clinical Sequencing News - Illumina Sees Clinical Applications for MiSeq; Plans FDA Submission in 2012
August 3, 2011 / Clinical Sequencing News - Next-Gen Sequencing: Hot as a Research Tool; Not for Qiagen's Companion Dx Strategy
July 20, 2011 / Pharmacogenomics Reporter - Sequenom Signs Supply Deal for T21 Test with Illumina; Firms to Collaborate on Regulatory Approval
July 12, 2011 / Clinical Sequencing News - Pharmigene’s Genetic Test for Carbamazepine Response Now Standard in 50 Taiwan Hospitals
April 13, 2011 / Pharmacogenomics Reporter